10-K: CS Diagnostics Corp. 2025 Annual Report: Revenue Growth Driven by Related-Party Dealings

CS Diagnostics Corp. reported a significant increase in revenue for fiscal year 2025, primarily due to an Affiliate Revenue Agreement, while facing ongoing liquidity constraints and a material weakness in internal controls.

Summary

• CS Diagnostics Corp. filed its 2025 Form 10-K, reporting total revenue of $204,000, a substantial increase from $110,911 in 2024, largely driven by a related-party Affiliate Revenue Agreement (ARA) providing $17,000 monthly.
• Operating expenses increased to $132,781 in 2025 from $110,150 in 2024, attributed to higher general and administrative costs for corporate and regulatory compliance.
• Net income for 2025 was $71,219, a significant rise from $761 in 2024 and a net loss of approximately $22,000 in 2023, primarily due to the ARA revenue.
• The company's asset base is dominated by intangible assets valued at approximately $499.4 million, primarily intellectual property for CS Protect-Hydrogel, with limited current assets of $85,555.
• Total liabilities increased to $15,262 in 2025 from $1,428 in 2024, mainly due to higher accounts payable.
• Liquidity remains constrained, with only $6,813 in cash as of December 31, 2025, and negative net cash used in operating activities of $6,312.
• The company identified a material weakness in internal control over financial reporting related to the period-end financial close process.
• The company's common stock is quoted on the OTCQB under the ticker CSDX, with a limited and sporadic market.
• No cash dividends have been paid and none are anticipated in the foreseeable future.
• The company has changed its independent registered public accounting firm multiple times, with Shah Teelani & Associates engaged in February 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a low score due to the company's precarious financial position, heavy reliance on related-party funding, and a material weakness in internal controls, despite positive net income driven by non-operational revenue.

Positives

• Revenue increased significantly to $204,000 in 2025, up from $110,911 in 2024, driven by the Affiliate Revenue Agreement.
• Net income turned positive at $71,219 in 2025, compared to a net income of $761 in 2024 and a net loss in 2023.
• Total assets increased slightly to $499,485,555 as of December 31, 2025, from $499,400,501 in 2024, primarily due to the substantial intangible asset value.
• Current assets saw a significant increase to $85,555 from $501, mainly due to higher cash balances.
• The company has no material long-term debt and operates with limited leverage.
• Management believes its plans, including capital raising and affiliate support, alleviate substantial doubt about its ability to continue as a going concern.
• Projected revenues at maturity for CS Protect-Hydrogel are estimated between $282 million and $303 million annually.
• The company expects the MEDUSA product to generate a 5% royalty on U.S. commercialization, anticipated to commence in Q3 2026.

Negatives

• Revenue is heavily reliant on a related-party Affiliate Revenue Agreement, which is non-arms length and can be terminated with 30 days' notice.
• The company has a material weakness in internal control over financial reporting related to the period-end financial close process.
• Liquidity is severely constrained, with only $6,813 in cash as of December 31, 2025.
• Net cash used in operating activities was $6,312, despite reporting net income, indicating a disconnect between earnings and cash flow.
• The company has not generated revenue from its core operations and has no measurable market share.
• The market for its common stock is limited and sporadic, with no assurance of an active trading market.
• The company has not paid any cash dividends and does not anticipate doing so in the foreseeable future.
• The company has experienced multiple changes in its independent registered public accounting firm.
• The substantial intangible asset value of $499.4 million is non-cash and its recoverability depends on future commercialization and regulatory approvals.
• The company has an accumulated deficit of $4,696,710 as of December 31, 2025.

Risks

• The company's strategy is dependent on obtaining and maintaining necessary regulatory approvals for its products.
• Market acceptance of its products is uncertain.
• The company faces supply chain dependencies and intellectual property risks.
• The Affiliate Revenue Agreement is a related-party transaction and may be terminated upon short notice, impacting revenue and liquidity.
• The recoverability of the significant intangible asset ($499.4 million) depends on successful future commercialization and regulatory approvals.
• The company's limited cash balance and negative operating cash flow raise concerns about its ability to meet ongoing obligations.
• Expected increases in operating costs associated with regulatory and commercialization activities could further strain financial resources.
• The company may not be able to obtain additional financing on acceptable terms, or at all, which is critical for its continued operations.
• The market for its common stock is illiquid, making it difficult for investors to trade shares.
• The company is subject to regulatory compliance risks in the highly regulated medical device industry.
• The company's reliance on third-party relationships for commercial functions introduces execution risks.

Future Outlook

The company's future performance hinges on obtaining regulatory approvals, generating product-based revenue, securing additional financing, and achieving market acceptance. While net income was reported for 2025, it was primarily due to related-party contributions and is not indicative of future operating performance. Projected revenues for CS Protect-Hydrogel are estimated between $282 million and $303 million annually at maturity, with a 5% royalty expected from MEDUSA product commercialization starting in Q3 2026, subject to regulatory approval.

Management Comments

• The Company attributes the increase in 2025 revenue primarily from a related-party Affiliate Revenue Agreement (ARA).
• The ARA revenue does not reflect revenue from third-party customers or the Company's core business operations and may not be indicative of future operating performance.
• The Company expects operating expenses to increase as it continues regulatory and commercialization activities; however, the timing and magnitude of such increases remain uncertain.
• The increase in net income for 2025 is primarily due to related-party revenue under the ARA, which may not recur.
• The Company's liquidity remains constrained, and its ability to meet obligations depends on continued support from affiliates and obtaining additional financing.
• Several known trends and uncertainties are reasonably likely to materially affect the Company's liquidity and financial condition, including the potential termination or modification of the ARA and the absence of revenue from product-based operations.
• Management plans to address liquidity constraints through equity financings, strategic partnerships, and the development of revenue-generating operations, but may not obtain such financing on acceptable terms, or at all.
• The Company does not have material commitments for capital expenditures as of December 31, 2025.
• Management believes that the Company's plans, including capital raising activities and affiliate support, are probable of implementation and expected to provide sufficient liquidity for at least 12 months, alleviating substantial doubt about its ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that CS Diagnostics Corp. operates in the highly regulated medical device and oncology support market, facing established competitors with existing FDA-approved products, clinical data, and distribution networks. The company's strategy relies heavily on securing regulatory approvals and leveraging third-party relationships for commercialization, a common approach for early-stage biotech and medtech firms, but one that carries significant execution risk.

Comparison to Industry Standards

• The company's revenue of $204,000 in 2025 is significantly lower than established players in the medical device sector, many of whom report revenues in the hundreds of millions or billions of dollars annually.
• The substantial intangible asset value of $499.4 million, representing nearly all of the company's assets, is a common characteristic for pre-commercialization biotech and medical device companies, where intellectual property is the primary asset. However, its recoverability is a key differentiator from companies with proven product sales.
• The company's cash position of $6,813 is critically low compared to industry standards, where even smaller, development-stage companies typically maintain higher cash reserves to fund ongoing operations and R&D.
• The reliance on related-party revenue for operational funding is not a sustainable industry standard; established companies typically generate revenue from third-party customer sales.
• The identification of a material weakness in internal controls is a concern, though many smaller, rapidly growing companies may face such challenges during their development phases. Remediation is crucial for investor confidence.

Corporate Governance

Related Party Transactions

• The company generated revenue through an Affiliate Revenue Agreement (ARA) with affiliated entities, providing fixed monthly contributions of $17,000 ($204,000 annually). This revenue is considered non-operational and may not be indicative of future performance.
• The intangible asset related to CS Protect-Hydrogel was recognized following an Asset Purchase Agreement with affiliated entities, with consideration consisting of the issuance of 10,000,000 shares of common stock.
• The MEDUSA product is produced by an affiliated entity, and the company expects to receive a 5% royalty on its U.S. commercialization.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings. The limited and sporadic market for common stock may hinder liquidity.
• Creditors: The company has minimal debt, but its ability to meet obligations depends on continued affiliate support and future financing.
• Employees: The company's financial precariousness and reliance on external funding could create job security concerns.
• Suppliers: The company's liquidity constraints could impact its ability to pay suppliers on time.
• Management: Faces significant challenges in navigating liquidity issues, achieving regulatory approvals, and remediating internal control weaknesses.

Next Steps

• Continue remediation efforts for the material weakness in internal control over financial reporting.
• Pursue capital-raising activities, including a Regulation D offering and strategic investor outreach.
• Obtain necessary regulatory approvals for CS Protect-Hydrogel.
• Commercialize CS Protect-Hydrogel, targeting market entry in 2026.
• Evaluate strategic monetization alternatives, including licensing, joint ventures, and commercialization partnerships.
• Begin recognizing royalty income from MEDUSA product commercialization, expected to commence in Q3 2026, subject to regulatory approval.

Key Dates

Recommendation

The company shows potential with its intellectual property and future revenue projections, but the significant risks associated with its liquidity, reliance on related-party transactions, and material weakness in internal controls warrant a cautious 'hold' recommendation. Investors should monitor the progress of capital raises, regulatory approvals, and internal control remediation.

Keywords

CS Diagnostics Corp., 10-K, Annual Report, Medical Devices, Oncology, CS Protect-Hydrogel, Intangible Assets, Affiliate Revenue Agreement, Liquidity, Going Concern, Regulatory Approval, SEC Filing